These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21947099)

  • 1. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
    Grau S; Rebollo P; Cuervo J; Gil-Parrado S
    Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
    Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
    Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
    Mave V; Garcia-Diaz J; Islam T; Hasbun R
    J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
    Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
    Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
    McComb MN; Collins CD
    Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
    Crank CW; Scheetz MH; Brielmaier B; Rose WE; Patel GP; Ritchie DJ; Segreti J
    Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
    King EA; McCoy D; Desai S; Nyirenda T; Bicking K
    J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
    Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
    Menzin J; Marton JP; Meyers JL; Carson RT; Rothermel CD; Friedman M
    Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
    Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
    Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
    Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
    Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
    Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
    Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.